Evaluation of growth hormone secretion and treatment.
The secretion of growth hormone (GH) is regulated by a complex system that includes both neurotransmitters and feedback by hormonal and metabolic substrates. Over the last few years it has been recognized that GH release varies over a wide spectrum from deficient to excessive secretion. The diagnosis of GH deficiency is based on a combination of anthropometric and clinical signs on the one hand and an inadequate stimulated and/or spontaneous GH secretion on the other. There is no distinct boundary between deficient and sufficient GH secretion. The cut-off limit for normal GH release is accordingly relative and has increased over the past decade from 5 to 10 micrograms/l. The effect of GH therapy on growth can be evaluated only after treatment for at least 6 months. There is, therefore, an indisputable need for methods that would reflect growth response soon after the start of treatment. There are several promising biochemical candidates, e.g. the aminoterminal propeptide of type III procollagen, the carboxyterminal propeptide of procollagen I and the bone Gla-protein, which may turn out to be useful early indicators of the growth response to long-term GH therapy.
Tapanainen
P
P
Department of Pediatrics, University of Oulu, Finland.
Knip
M
M
D013006:Growth Hormone / Q000172:deficiency / Q000378:metabolism* / Q000627:therapeutic use; D013007:Growth Hormone-Releasing Hormone / Q000378:metabolism; D006801:Humans; D013997:Time Factors; D016896:Treatment Outcome
D013006:Growth Hormone; D013007:Growth Hormone-Releasing Hormone